

Special Issue

Cellular and Immunotherapy for Acute Lymphoblastic Leukemia

Message from the Guest Editors

Acute lymphoblastic leukemia (ALL) affects both adults and children and is the most common pediatric malignancy. ALL is traditionally treated with cytotoxic chemotherapy agents, yet despite improvement in outcomes there is still a subset of patients who do not respond or relapse after chemotherapy. Advances in cellular therapy and immunotherapy provide therapeutic alternatives or adjuncts to chemotherapy which is especially important for those with refractory or relapsed disease. This special issue will explore advances in the pathogenesis of Acute Lymphoblastic Leukemia and cellular and immunotherapy for the treatment of ALL including chimeric antigen receptor T-cell therapy and monoclonal antibody therapy.

Guest Editors

Dr. Hisham Abdel-Azim

Keck School of Medicine, Children Hospital Los Angeles, University Of Southern California, Los Angeles, CA, USA

Dr. Rachel Gallant

Children Hospital Los Angeles, Los Angeles, CA, USA

Dr. Kris M. Mahadeo

MD Anderson Cancer Center, University of Texas, Houston, TX, USA

Deadline for manuscript submissions

closed (31 October 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/68298

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).